Sable Bio offers an AI-driven safety intelligence platform that aggregates millions of scientific papers and reports to surface potential toxicity risks associated with drug targets. The system employs bespoke natural-language models and causal inference techniques to distinguish true safety signals from background noise, presenting ranked insights for scientists. By unifying fragmented data sources, the product aims to cut costly late-stage failures and accelerate decision-making in drug discovery. Over the last twelve months, the company generated approximately $0.5 million in revenue and has secured commercial agreements with multiple pharma companies, including three of the global top ten. Management plans to use fresh capital to expand the London team, enhance product capabilities, and integrate real-world evidence into the platform. Future growth will also focus on forging additional partnerships across biotech, pharmaceutical, and health-tech sectors. Ultimately, Sable Bio envisions its platform becoming a system of record for target safety assessment throughout the industry.

Total raised

$6M

Funding rounds

2

Latest round

Seed

Latest activity

Feb 2026